- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Alembic Pharmaceuticals: CRISIL Ratings has reaffirmed its 'CRISIL AA+/Stable' rating for the company's long-term Bank Loan Facilities, now enhanced to Rs. 1,100 Cr from Rs. 800 Cr. Additionally, CRISIL reaffirmed the 'CRISIL A1+' rating for its Commercial Paper of Rs. 1,100 Cr. The outlook for long-term facilities remains Stable.